IMI/REL + Active Control + Oral Switch
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Suspected or Documented Gram-negative Bacterial Infection
Conditions
Suspected or Documented Gram-negative Bacterial Infection
Trial Timeline
Oct 8, 2019 → May 7, 2024
NCT ID
NCT03969901About IMI/REL + Active Control + Oral Switch
IMI/REL + Active Control + Oral Switch is a phase 2/3 stage product being developed by Merck for Suspected or Documented Gram-negative Bacterial Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03969901. Target conditions include Suspected or Documented Gram-negative Bacterial Infection.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03969901 | Phase 2/3 | Completed |
Competing Products
6 competing products in Suspected or Documented Gram-negative Bacterial Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KHK4563 + KHK4563 + KHK4563 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| Ceftazidime-avibactam | AbbVie | Phase 1 | 33 |
| IMI/REL FDC | Merck | Phase 1 | 33 |
| Ceftolozane/Tazobactam 1000/500 mg + Ceftolozane/Tazobactam 30/15 mg/kg + Ceftolozane/Tazobactam 20/10 mg/kg + Ceftolozane/Tazobactam 18/9 mg/kg + Ceftolozane/Tazobactam 12/6 mg/kg | Merck | Phase 1 | 33 |
| Gadoxetic Acid Disodium (Primovist, BAY86-4873) | Bayer | Phase 3 | 74 |
| TD-1607 + Placebo | Theravance Biopharma | Phase 1 | 28 |